Tuesday, October 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

Procter & Gamble posts earnings beat: CFO on the results

View original at finance.yahoo.com
Procter & Gamble posts earnings beat: CFO on the results Procter & Gamble (PG) reported adjusted earnings of $1.88 per share and revenue of $22.2 billion for its fiscal second quarter…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • P&G reduced tariff exposure through productivity work, sourcing changes, formulation changes, and innovation-based pricing

    80% confidence
  • If base effect of inventory loading is removed, US would have already shown growth

    80% confidence
  • Typical category growth rate is 3-4%, and current 1-2% growth is slower than normal

    80% confidence
  • P&G firmly believes categories will return to 3-4% growth over time

    80% confidence
  • P&G offers three tiers of diapers: Swaddlers (super premium), Baby Dry (mid-tier), and Luvs (value tier close to private label pricing)

    80% confidence
  • P&G categories in US have grown between 1-2% in value growth and flat in volume growth over past three months

    80% confidence
  • Tariff exposure reduced from $1 billion at beginning of year to $400 million after tax

    80% confidence
  • US economy is growing at 4-5% and could continue at that growth rate

    80% confidence
  • Business outside the US is growing 3% with Latin America at 8%, China at 3%, Europe at 3%, and Asia/Africa at 2%

    80% confidence
  • Gillette is one of P&G's most profitable businesses from an operating margin perspective

    80% confidence
  • Six figure jobs are being created from AI data centers

    80% confidence
  • US had weak shipment quarter due to significant inventory build in base year from two port strikes and hurricane about a year ago

    80% confidence
  • P&G consumption in US over last three months would have been 1.5% to 2% in value terms excluding pantry loading

    80% confidence
  • Innovation capabilities across biology, chemistry, fiber technology, assembled products, and electronics have never been stronger

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com
Procter & Gamble posts earnings beat: CFO on the results — Source | Via News | Via News